Posted on

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; “MindMed” or the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.

Mr. Krebs is an internationally experienced executive, entrepreneur and best-selling author (“The Illusion of Invincibility”). He heads the family-owned investment company Longfield Invest (Langenfeld/Germany), which focuses on growth companies in various industries as well as in the new economy. He has worked in seven countries, in Latin America, Asia and Canada and as President and Executive Board Member of Wyeth Corporation in the United States. Andreas Krebs was Chairman of the Supervisory Board and Shareholder Council of Merz Pharma, Frankfurt am Main, Germany from 2010 to 2019, is currently a member of the Supervisory Board of the European eye clinic group Veonet (Nordic Capital Group) and holds other board positions across various sectors.  Furthermore, he serves as Chairman of the private non-governmental organization, Förderverein Girassol eV, which supports children and young people from socially difficult backgrounds in São Paulo, Brazil.

Ms. Vallone is a well-known business leader, former CEO, and corporate board director, with a strong track record in launching, scaling and selling global companies. Currently, she serves as Chair of the Board of Trustees at McLean Hospital, the #1 ranked freestanding psychiatric hospital and largest psychiatric affiliate of Harvard Medical School; serves on the board of trustees at MGH Institute of Health Professions; and serves on the finance committee at Mass General Brigham. Additionally, Ms. Vallone serves as a board member for the publicly traded Cresco Labs, and for a Bain Capital Double Impact portfolio company, Arosa. She is also an Advisory Director for the investment firm, Berkshire Partners and an Advisory Board Member of the healthcare-focused venture growth firm, Longitude Capital. A serial entrepreneur, Ms. Vallone has served as founder & CEO of global e-learning companies, held manager positions in leading corporate technology companies and served on the boards of public financial services and e-commerce organizations.

Mr. Krebs said, “Mental health issues directly or indirectly impact almost every one of us at some point in our lives. I’m thrilled at the opportunity to help MindMed find better solutions to this huge challenge in the coming years.”

Ms. Vallone said, “I feel privileged to support MindMed’s esteemed team of scientists and business professionals in the pursuit of new medicines and therapies for those who suffer with mental illness.”

Effective September 29, 2021, Mr. Bruce Linton stepped down from the Company’s board of directors in order to make room for the appointment of Ms. Vallone and Mr. Krebs. Mr. Linton said, “In a little over two years MindMed has gone from a topic that was frankly difficult to find support for, to attracting world class talent and deep capacity capital.” He added further “I am delighted with the candidates joining and look forward to the world of change MindMed can achieve.”

MindMed Chair Perry Dellelce said, “We are extremely happy to welcome Carol and Andreas to the Board. The depth of their collective experience with pharma, tech and health-focused organizations, combined with their extensive service on public company boards, will broaden and deepen the capabilities of the Company’s board of directors. As well, on behalf of the board of directors I would like to thank Bruce for his committed support and service on the Company’s board since the Company’s inception. I look forward to working with him on his next ventures.”

The appointment of Mr. Krebs and Ms. Vallone is subject to regulatory approval.

 

About MindMed

 MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding Mr. Krebs’ and Ms. Vallone’s appointment to the Company’s board of directors, regulatory approval and the intended future business plans and operations. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Posted on

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board.

Dr. Roth has spent over 30 years studying molecular neuropharmacology. He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina’s (UNC) School of Medicine. He is also the director of the National Institute of Mental Health Psychoactive Drug Screening Program.

Dr. Roth’s research focuses on removing the hallucinogenic effects from psychedelic drugs; eliminating the hours-long hallucinatory trips that may turn some patients away from psychedelic-assisted treatments. He was among the first to publish in the scientific journal, Cell, the structure of how LSD binds to serotonin receptors within the brain. This structure is crucial to help scientists understand why psychedelics can have hallucinogenic and therapeutic effects.

Dr. Roth’s search for drugs that bind to and activate serotonin receptors without causing a psychedelic experience secured a $27 million grant from the Defense Advanced Research Projects Agency , a research and development agency of the US Department of Defense that helps advance emerging technologies. The grant helped fund Ultra Large-Scale-Docking, a computer program which can generate a billion theoretical psychedelic compounds that all score differently in how they activate the 5-HT-2A serotonin receptor. Dr. Roth’s team is studying the compounds Ultra Large-Scale-Docking  identifies which are the likeliest to activate the serotonin receptor without triggering hallucinations.

MindMed CEO Robert Barrow said, “We are thrilled to welcome Dr. Roth to our Scientific Advisory Board. In the pursuit of reimagining mental health and addiction care, we want to ensure the treatments we’re studying are effective and accessible for as many patients as possible. Dr. Roth’s extensive experience in psychiatry and pharmacology will be invaluable in progressing all of our research and development efforts.”

Dr. Roth noted, “Psychedelic compounds like psilocybin have some of the most robust antidepressant effects I’ve ever seen in Phase II studies. But not all patients are comfortable with their treatment program requiring hallucinatory trips. My research, and the perspective I’m excited to bring to MindMed’s drug development programs, focuses on how we can make drugs that are maximally helpful to patients while minimizing discomfort in the treatment process.”

MindMed’s Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development. The Scientific Advisory Board leverages decades of experience in biotechnology and psychiatry to guide MindMed’s development programs. Members represent institutions such as Johns Hopkins University, New York University Langone Health, Duke University, the National Institutes of Health, Stanford University, and Massachusetts General Hospital

About MindMed

MindMed is a clinical-stage psychedelic medicine biotechnology company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. MindMed is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding MindMed’s Scientific Advisory Board, Dr. Roth’s research in psychedelic drugs and his potential discoveries and the ability of MindMed to leverage the knowledge and expertise of members of its Scientific Advisory Board. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Posted on

Clearmind Medicine To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company

Clearmind Medicine To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company

Toronto, Ontario–(Newsfile Corp. – September 27, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an agreement to fund a second research and development project with Yissum Research Development Company (“Yissum”), the technology transfer company of The Hebrew University of Jerusalem.

The project is consistent with the Company’s focus on developing novel therapies that improve mental health, particularly those relating to addiction, binge behavior and depression.

About Yissum Research Development Corporation

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875+ patents globally; licensed over 1140+ technologies and has spun out more than 191 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il.

About the Hebrew University of Jerusalem

The Hebrew University of Jerusalem is Israel’s first university, formed in 1918 and opened in 1925. Today, there are over 23,000 students enrolled at the University, including undergraduates, master’s degree students, and doctoral candidates. The university has four campuses: Mount Scopus, The Edmond J. Safra (Givat Ram) Campus, and Ein Kerem (in Jerusalem), and Rehovot. Hebrew University Alumni are invited to visit https://new.huji.ac.il.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWYO.”

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE“) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

Posted on

Its now safe to vape government funded shrooms on antidepressants: issue 16

Here’s what’s in store for you in today’s issue:

🍄 Combining psilocybin with antidepressants

🍄 Vaping mushrooms?

🍄 The cure for constant hunger

🍄 Government-funded shroom trip

🍄 And more.

You’ll want to stay till the end to learn how someone gained a new skill during their first trip!

(Did a good friend forward this to you? If so be sure to subscribe here)

Be sure to check out this week’s Daily Mushroom podcast!
Psilocybin, is it the next cannabis wave?

In this episode we have Lenny Kerman, a strategic financial consultant who works with various psilocybin and cannabis companies. He talks about how he’s invested in the space and has some valuable information for those looking to invest as well.

Therapeutic banner

Psilocybin or antidepressants? Why not both!

A new study found that combining SSRIs and psilocybin is not only safe, but may be beneficial!

Yesterday, MindMed (MNDM) announced the findings from an ongoing study conducted in collaboration with UHB Liechti Lab.

Psilocybin was found to be safe to administer with an SSRI antidepressant and did not reduce the psychedelic experience. Two weeks prior to the psilocybin dose, volunteers were give a daily pretreatment of the SSRI escitalopram. As a result, the volunteers experienced reduced anxiety and blood pressure increases that can occur with psilocybin administration.

The cure for constant hunger

Can shrooms treat this rare genetic disorder?

Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.

The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.

The San Diego company just filed an Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.

Say goodbye to extreme anxiety

Mydecine (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.

The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care.

The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).

Mydecine (MYCO) filed a patent for a new anxiety and PTSD drug that provides more immediate relief than pure psilocybin.

The compound, MYCO-003, combines a serotonin agonist with a serotonin releasing agent – two drug classes that increase one’s sense of well-being, safety, and happiness. The formulation has shown positive preclinical data and has potential to relieve extreme anxiety before needing to provide extensive supportive care.

The patent was filed with both the United States Patent and Trademark Office (USPTO) and the World Intellectual Property Organization (WIPO).

inspirational banner

Government-funded shroom trip

After half a century, the US federal government has started funding psychedelic research again!

A researcher at Johns Hopkins University received a U01 grant from the National Institute on Drug Abuse (NIDA) to fund a multi-site study on psilocybin for tobacco addiction, which will take place at Johns Hopkins, New York University, and the University of Alabama at Birmingham.

The researcher, Dr. Matthew W. Johnson, noted that this is the first time a psychedelic study has received funding since the War on Drugs was declared in the 70s, marking a “new era in legitimacy of psychedelic science”.

Microdosing research expands worldwide!

Yesterday, Wake Network Inc. received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for PSIL428, its microdose formulation made from natural psilocybin.

The certification allows the company to run clinical trials on anxiety and depression and makes PSIL429 available to clinics and academic institutions across the globe. Any country with a special access program can request to import the legal formulation for patient use.

In other microdosing news, MindBio Therapeutics, a subsidiary of Blackhawk Growth Corp. (BLR), is partnering with Trip Pharma’s LeichtMind clinic to launch microdosing clinical trials in Canada!

business banner

Let me hit that vape

Will psychedelic therapy soon involve vaping shrooms?

Delic (DELC) is the first company to receive Health Canada approval to research psilocybin vaporization.

On Monday, Delic entered into an agreement to acquire Ketamine Wellness Clinics, a company that runs 10 ketamine infusion centers across 8 states. The deal increases Delic’s total number of clinics to 12 and adds over 60 medical professionals to the team, making it the largest psychedelic wellness chain in the US. Within the next 18 months, the company hopes to grow this number to 27 clinics!

Once granted FDA-approval, DELIC aims to offer other psychedelic treatments at these locations including MDMA and psilocybin therapy, which could potentially use the vaporization technology!

Optimizing psychedelic therapy…there’s an app for that!

MINDCURE’s (MCUR) digital therapeutics platform could improve the psychedelic healing journey for both patients and clinicians!

The software application, iSTRYM, provides clinicians with a global database of therapy protocols, integration plans, and AI-driven data insights into patient journeys. The application connects to mobile and wearable devices to measure patients’ biological response to the treatment, allowing clinicians to provide personalized care. iSTRYM also offers a Mindfulness Suite that patients can use to explore practices like breathwork and meditation to support their healing. 

This week, MINDCURE signed into an exclusive licensing agreement with ATMA Journey Centers, a private psychedelic therapy clinic in Calgary, which will grant MINDCURE access to anonymous patient data gathered from ATMA’s use of the platform.

legal banner

Half a million Italians want to decriminalize mushrooms!

You may want to postpone your trip to Italy till next year 😉

Italian activists collected 500,000 signatures in favour of a referendum to decriminalize marijuana and psilocybin – enough to qualify for a ballot measure!

The referendum would remove Italy’s prohibition on cultivating psychoactive substances, but the further processing required to produce most narcotics would remain illegal. Fortunately, magic mushrooms are ready to enjoy after cultivation alone! 

A vote is expected to take place in spring of 2022 given that the Court of Cassation and the Constitutional Court sign off on the measure after reviewing the petition. 

Perpetuating the worst research blackout in history

Back in May, UK Prime Minister Boris Johnson approved the rescheduling of psilocybin to make it easier to research its therapeutic effects.

Months have passed, yet the Home Office has failed to act, “perpetuating what can be considered the worst research blackout in scientific history,” according to the Conservative Drug Policy Reform Group (CDPRG). Crispin Blunt MP, chairman of the CDPRG, is urging the Home Office to take action fast to tackle the mental health crisis. 

A Home Office spokesperson said that there are currently no plans to reschedule psilocybin due to the Misuse of Drugs Regulations 2001, but they will consider any recommendations from The Advisory Council on the Misuse of Drugs (ACMD), which is reviewing the barriers to researching controlled drugs.

Industry Quick Hits

Sept 21 – Eversio Wellness Harvests Its First Legally Grown Psychoactive Mushrooms Read more…

Sept 21 – Clearmind Medicine (CMND) Partners with The Hebrew University to Develop Novel Psychedelic Drug Read more…

Sept 21 – FSD Pharma (HUGE) Announces Closing Of Lucid Psycheceuticals Acquisition Read more… 

Sept 23 – Havn Life (HAVN) Announces Supply And Distribution MOU With Mycrodose Therapeutics Read more…

Sept 23 – Numinus (NUMI) Completes Acquisition of Neurology Centre of Toronto Read more…

Sept 23 – Delic (DELC) Announces C$7.0 Million Private Placement With Institutional Investor Read more…

Sept 24 – Novamind (NM) Announces DTC Eligibility for its Common Shares Read more…

Sept 24 – PharmaTher (PHRM) Announces CAD$10 Million Private Placement With Institutional Investors Read more…

Video of the Week

History of Magic Mushrooms

New superpower unlocked

This Reddit user gained a new ability during their first trip.

“I’m in my 40s and have been tone deaf as well as having hearing loss my whole life. I can’t carry a tune or recognize notes/melodies, and have never connected emotionally to music. When I dance, I’m just imitating others. I don’t know how to dance to music.

I tried magic mushrooms for the first time. My friend had music playing and at one point during my trip, I started humming and singing. I became the song and my body knew how to dance and play an instrument. My fingers were making the most intricate, precise movements- strumming an instrument like a professional musician. Dance movements came to me and I could feel it in my nervous system as I danced. Afterwards, I was still ready to believe that I was probably horribly out of tune and stumbling around and making stuff up, but my friend- who was not tripping- confirmed that I was carrying a tune, humming the song that was playing, and danced as if I had been trained and done it all my life.

This is just… unbelievable. And also merely a facet of the whole trip! I’d love to hear if this resonates with others and if there have been similar experiences!”

Playlist of the Week

Trippy playlist for all
mushroom balloon
Posted on

MindMed to present at the Benzinga Healthcare Small Cap Conference

MindMed to present at the Benzinga Healthcare Small Cap Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will be speaking at the Benzinga Healthcare Small Cap Conference, taking place on September 29-30, 2021.

Barrow will be giving an exclusive interview at 11:30am ET on September 30. A replay of the session will be available within 48 hours after the event and will be accessible in the “Investor” section of MindMed’s website for 30 days following the event.

 

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding MindMed’s participation at the Benzinga Healthcare Small Cap Conference. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Posted on

Psilocybin or SSRIs? Why not both!

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

A new study found that combining SSRIs and psilocybin is not only safe, but may be beneficial!

Yesterday, MindMed (MNMD) announced the findings from several ongoing studies conducted in collaboration with UHB Liechti Lab.

In one study, psilocybin was found to be safe to administer with an SSRI antidepressant and did not reduce the psychedelic experience. Two weeks prior to the psilocybin dose, volunteers were give a daily pretreatment of the SSRI escitalopram. As a result, the volunteers experienced reduced anxiety and blood pressure increases that occur with psilocybin administration.

Another study compared the perceptual effects of psilocybin to LSD and revealed that a 20 mg dose of psilocybin is equivalent to 100 mcg of LSD.

The company will continue to analyze the study data and will publish additional findings later this year.

PDF of article

 

Posted on

Clearmind Medicine (CMND) Partners with The Hebrew University to Develop Novel Psychedelic Drug

The R&D project with Yissum Research Development Company will contribute to Clearmind’s IP portfolio

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has established a research and development project with Yissum Research Development Company (“Yissum”), the technology transfer company of The Hebrew University of Jerusalem. The collaboration will focus on developing novel, innovative, patentable psychedelics as potential drug candidates to expand Clearmind’s IP portfolio.

Yissum is known for its ability to discover, analyze and design advanced molecular scaffolds to serve as common platforms for synthesizing various structurally related compounds as potential therapeutic agents and drug candidates.

According to the terms of the agreement, The Hebrew University researchers, professors Dmitry Tsvelikhovsky, Masha Niv and Avi Priel, will work together to investigate and innovate synthetic novel analogs of known psychedelic compounds, conduct in silico 3D docking studies and rational design, and screen the compounds in an in vitro platform.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “This is an important partnership for Clearmind. The academic/technology transfer model is responsible for many medical breakthroughs, and the Hebrew University-Yissum partnership is one of the most prolific in the field. I am certain that our collaboration will yield many potential candidates for further evaluation.”

“Yissum is looking forward to collaborating with Clearmind in its mission to discover novel psychedelic compounds. We have assigned our top researchers from multiple fields to this project, and I am confident their broad expertise and know-how will facilitate Clearmind’s ability to expand their pipeline portfolio,” said Dr. Ilya Pittel, VP of business development at Yissum Research Development Company.

Professor Tsvelihovsky added, “Professors Avi Priel and Masha Niv and I are excited to work with the team at Clearmind to create unique synthetic compounds for the development of novel GPCR-focused therapeutics. We believe psychedelics are going to revolutionize the treatment of mental health, and Clearmind’s plans put it on the leading edge of innovation in the field. We are quite optimistic that our efforts will lead to new psychotherapy drug candidates.”

About Yissum Research Development Company

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors and industry. Yissum’s mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,875 patents globally, licensed over 1,140 technologies and has spun out more than 191 companies. Yissum’s business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information, please visit www.yissum.co.il.

About the Hebrew University of Jerusalem

The Hebrew University of Jerusalem is Israel’s first university, formed in 1918 and opened in 1925. Today, there are over 23,000 students enrolled at the university, including undergraduates, master’s degree students and doctoral candidates. The university has four campuses: Mount Scopus, The Edmond J. Safra (Givat Ram) Campus, and Ein Kerem, all in Jerusalem, and Robert H. Smith Faculty of Agriculture, Food and the Environment, located in Rehovot. Hebrew University Alumni are invited to visit https://new.huji.ac.il.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWYO.”

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Wire Service Contact
InvestorWire
Los Angeles, California
www.InvestorWire.com
212.418.1217
Editor@InvestorWire.com

Posted on

MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.

A video webcast of the presentation will be available for viewing on-demand beginning on Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible in the “Investors” section of MindMed’s website. MindMed will maintain an archived replay of the webcast on its website for 30 days after the conference.

 

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding the H.C. Wainwright 23rd Annual Global Investment Conference, management attendance at the conference and the ability of institutional investors to speak with members of MindMed’s management. . Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Posted on

MindMed to Attend 8th Annual “Mobile in Clinical Trials” Conference

MindMed to Attend 8th Annual “Mobile in Clinical Trials” Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.

“I’ve always enjoyed co-chairing Mobile in Clinical Trials, together with my friend Michelle Shogren from Bayer,” said Dr. Karlin. “We would have preferred a hybrid option allowing for in person interactions but the safety of attendees comes first. Last year’s virtual format still enabled the fruitful exchange of the latest knowledge in the area of digital solutions, just as we had experienced during previous years of Mobile in Clinical Trials that took place in person.”

The 8th annual Mobile in Clinical Trials Conference will feature the latest examples of deploying remote digital tools in clinical studies and will offer solutions for making digital technology an integral part of clinical research. Mobile in Clinical Trials is the event most attended by digital R&D operations leaders who are seeking solutions to apply mobile-digital tools into clinical research. Each year at this Conference, participants present experience-based case studies and exchange fresh ideas to advance fit-for-purpose adoption and scale-up of remote digital solutions in the area of clinical research.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding MindMed’s attendance at the Mobile in Clinical Trials Conference, Conference program and topics and Conference attendees. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.